Opus Genetics, Inc.
$4.20
+5.3%Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.3).
Valuation inputs: P/E -5.3, earnings yield N/A, momentum +5.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -3.2%, ROIC -90.9%).
Profitability stack: net margin -3.5%, ROE -3.2%, ROIC -90.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +69.5%, momentum +5.3%, net margin -3.5%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Opus Genetics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Opus Genetics, Inc. Fair Value Envelope
Opus Genetics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Opus Genetics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Opus Genetics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Opus Genetics, Inc. Street Expectations Map
Wall Street analysts project that IRD stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 8.67, with estimates ranging from a low of 7.00 to a high of 10.00.
The consensus 1-year price target stands at 8.67, with estimates ranging from a low of 7.00 to a high of 10.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Opus Genetics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.26M and sold $16.49M worth of IRD shares, resulting in $15.23M of net selling activity.
3 Months
0
0.00
1.8M
7.78M
-7.8M
-$7.78M
3-6 Months
81.0K
160.27K
4.0M
8.60M
-8.4M
-$8.44M
6-9 Months
0
0.00
54.1K
116.20K
-116K
-$116K
9-12 Months
956.5K
1.10M
0
0.00
+1.1M
+$1.10M
Top Buyers
Gallagher Cam
Director
$1.16M
Ainsworth Sean
Director
$100K
Top Sellers
Foundation Fighting Blindness Retinal Degeneration Fund
Director, Other: See Remarks
$15.99M
Magrath George
Director, Officer: Chief Executive Officer
$247K
Yerxa Benjamin R
Director, Officer: President
$86K
Jayagopal Ashwath
Officer: Chief Scientific & Dev. Ofc.
$58K
Schachle Joseph K
Officer: Chief Operating Officer
$44K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $15.23M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
IRD has not reported any dividend yield values in the available annual periods.
ird Dividend History
Learning Layer
Related Guides
Build conviction on IRD by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.